Recombinant allergens for pollen immunotherapy

Immunotherapy

Volumn 5, Issue 12, 2013, Pages 1323-1338

  Wallner, Michael ^a   Pichler, Ulrike ^a   Ferreira, Fatima ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Grass pollen allergy; immunotherapy; modified allergens; recombinant allergens; tree pollen allergy; weed pollen allergy

Indexed keywords

BEE VENOM; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; POLLEN ANTIGEN; PROFILIN; RECOMBINANT ALLERGEN; TRANSCRIPTION FACTOR GATA 3;

ALLERGENICITY; AMARANTHACEAE; AMINO ACID SEQUENCE; ARTEMISIA VULGARIS; BIRCH; CELL INCLUSION; CHENOPODIUM; CROSS REACTION; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DELETION MUTANT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENETIC IMMUNIZATION; GEOBACILLUS STEAROTHERMOPHILUS; GRASS POLLEN; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOGENICITY; IMMUNOTHERAPY; MEDIATOR RELEASE; MULTICENTER STUDY (TOPIC); NICOTIANA BENTHAMIANA; NONHUMAN; OLIVE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEUM PRATENSE; POINT MUTATION; POLLEN ALLERGY; POLLEN IMMUNOTHERAPY; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; RAGWEED; RAGWEED POLLEN; REVIEW; RHINOCONJUNCTIVITIS; RHIZOBIUM RADIOBACTER; SENSITIZATION; SKIN SENSITIVITY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WEED;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; PLANT WEEDS; POACEAE; POLLEN; RECOMBINANT PROTEINS; TREES;

EID: 84889574195     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.114     Document Type: Review

References (98)

1. Breiteneder H, Hassfeld W, Pettenburger K et al. Isolation and characterization of messenger RNA from male inflorescences and pollen of the white birch (Betula verrucosa). Int. Arch. Allergy Appl. Immunol. 87(1), 19-24 (1988).
2. Thomas WR, Stewart GA, Simpson RJ et al. Cloning and expression of DNA coding for the major house dust mite allergen Der p 1 in Escherichia coli. Int. Arch. Allergy Appl. Immunol. 85(1), 127-129 (1988).
3. Fang KS, Vitale M, Fehlner P, King TP. cDNA cloning and primary structure of a white-face hornet venom allergen, antigen 5. Proc. Natl Acad. Sci. USA 85(3), 895-899 (1988). (Pubitemid 18073934)
4. Cromwell O, Hafner D, Nandy A. Recombinant allergens for specific immunotherapy. J. Allergy Clin. Immunol. 127(4), 865-872 (2011).
5. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 57(5), 423-430 (2002). (Pubitemid 34442156)
6. Pauli G, Larsen TH, Rak S et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 122(5), 951-960 (2008).
7. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 116(3), 608-613 (2005). (Pubitemid 41267135)
8. D'Amato G, Cecchi L, Bonini S et al. Allergenic pollen and pollen allergy in Europe. Allergy 62(9), 976-990 (2007). (Pubitemid 47220965)
9. Hauser M, Asam C, Himly M et al. Bet v 1-like pollen allergens of multiple Fagales species can sensitize atopic individuals. Clin. Exp. Allergy 41(12), 1804-1814 (2011).
10. Moverare R, Westritschnig K, Svensson M et al. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization. Int. Arch. Allergy Immunol. 128(4), 325-335 (2002).
11. Wallner M, Erler A, Hauser M et al. Immunologic characterization of isoforms of Car b 1 and Que a 1, the major hornbeam and oak pollen allergens. Allergy 64(3), 452-460 (2009).
12. Breiteneder H, Ferreira F, Hoffmann-Sommergruber K et al. Four recombinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties. Eur. J. Biochem. 212(2), 355-362 (1993). (Pubitemid 23076101)
13. Breiteneder H, Ferreira F, Reikerstorfer A et al. Complementary DNA cloning and expression in Escherichia coli of Aln g I, the major allergen in pollen of alder (Alnus glutinosa). J. Allergy Clin. Immunol. 90(6 Pt 1), 909-917 (1992). (Pubitemid 23004587)
14. Vrtala S, Hirtenlehner K, Vangelista L et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J. Clin. Invest. 99(7), 1673-1681 (1997). (Pubitemid 27163818)
15. Vrtala S, Hirtenlehner K, Vangelista L et al. Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments. Int. Arch. Allergy Immunol. 113(1-3), 246-248 (1997). (Pubitemid 27160772)
16. Vrtala S, Akdis CA, Budak F et al. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J. Immunol. 165(11), 6653-6659 (2000).
17. Vrtala S, Hirtenlehner K, Susani M et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J. 15(11), 2045-2047 (2001).
18. Campana R, Vrtala S, Maderegger B et al. Altered IgE epitope presentation: a model for hypoallergenic activity revealed for Bet v 1 trimer. Mol. Immunol. 48(4), 431-441 (2011).
19. Vrtala S, Fohr M, Campana R, Baumgartner C, Valent P, Valenta R. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine 29(11), 2140-2148 (2011).
20. Campana R, Vrtala S, Maderegger B et al. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. J. Allergy Clin. Immunol. 126(5), 1024-1031, 1031.e1021-1028 (2010).
21. Wallner M, Stocklinger A, Thalhamer T et al. Allergy multivaccines created by DNA shuffling of tree pollen allergens. J. Allergy Clin. Immunol. 120(2), 374-380 (2007). (Pubitemid 47102390)
22. Kahlert H, Suck R, Weber B et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int. Arch. Allergy Immunol. 145(3), 193-206 (2008). (Pubitemid 351301311)
23. Meyer W, Narkus A, Salapatek AM, Hafner D. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy 68(6), 724-731 (2013).
24. Thalhamer T, Dobias H, Stepanoska T et al. Designing hypoallergenic derivatives for allergy treatment by means of in silico mutation and screening. J. Allergy Clin. Immunol. 125(4), 926-934.e910 (2010).
25. Wallner M, Hauser M, Himly M et al. Reshaping the Bet v 1 fold modulates Th polarization. J. Allergy Clin. Immunol. 127(6), 1571-1578.e1579 (2011).
26. Kitzmuller C, Wallner M, Deifl S et al. A hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and T-cell activation. Allergy 67(11), 1375-1382 (2012).
27. Ferreira F, Hirtenlehner K, Jilek A et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J. Exp. Med. 183(2), 599-609 (1996). (Pubitemid 26059521)
28. Wallner M, Himly M, Neubauer A et al. The influence of recombinant production on the immunologic behavior of birch pollen isoallergens. PLoS ONE 4(12), e8457 (2009).
29. Focke M, Linhart B, Hartl A et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin. Exp. Allergy 34(10), 1525-1533 (2004). (Pubitemid 39389328)
30. Marth K, Breyer I, Focke-Tejkl M et al. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J. Immunol. 190(7), 3068-3078 (2013).
31. Twaroch TE, Focke M, Civaj V et al. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy. J. Allergy Clin. Immunol. 128(1), 178-184. e177 (2011).
32. Bohle B, Breitwieser A, Zwolfer B et al. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J. Immunol. 172(11), 6642-6648 (2004). (Pubitemid 38669099)
33. Bublin M, Hoflehner E, Wagner B et al. Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses. Vaccine 25(50), 8395-8404 (2007). (Pubitemid 350137603)
34. Wild C, Wallner M, Hufnagl K et al. A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities. Allergy 62(1), 33-41 (2007). (Pubitemid 44902732)
35. Hoflehner E, Hufnagl K, Schabussova I et al. Prevention of birch pollen-related food allergy by mucosal treatment with multi-allergen-chimers in mice. PLoS ONE 7(6), e39409 (2012).
36. Lombardero M, Obispo T, Calabozo B, Lezaun A, Polo F, Barber D. Cross-reactivity between olive and other species. Role of Ole e 1-related proteins. Allergy 57(Suppl. 71), 29-34 (2002). (Pubitemid 34442140)
37. Batanero E, Crespo JF, Monsalve RI, Martin-Esteban M, Villalba M, Rodriguez R. IgE-binding and histamine-release capabilities of the main carbohydrate component isolated from the major allergen of olive tree pollen, Ole e 1. J. Allergy Clin. Immunol. 103(1 Pt 1), 147-153 (1999). (Pubitemid 29063204)
38. Marazuela EG, Rodriguez R, Barber D, Villalba M, Batanero E. Hypoallergenic mutants of Ole e 1, the major olive pollen allergen, as candidates for allergy vaccines. Clin. Exp. Allergy 37(2), 251-260 (2007). (Pubitemid 46148283)
39. Charpin D, Calleja M, Lahoz C, Pichot C, Waisel Y. Allergy to cypress pollen. Allergy 60(3), 293-301 (2005). (Pubitemid 40293344)
40. Hashimoto M, Nigi H, Sakaguchi M et al. Sensitivity to two major allergens (Cry j I and Cry j II) in patients with Japanese cedar (Cryptomeria japonica) pollinosis. Clin. Exp. Allergy 25(9), 848-852 (1995).
41. Iacovacci P, Pini C, Afferni C et al. A monoclonal antibody specific for a carbohydrate epitope recognizes an IgE-binding determinant shared by taxonomically unrelated allergenic pollens. Clin. Exp. Allergy 31(3), 458-465 (2001). (Pubitemid 34204168)
42. Rea G, Iacovacci P, Ferrante P et al. Refolding of the Cupressus arizonica major pollen allergen Cup a1.02 overexpressed in Escherichia coli. Protein Expr. Purif. 37(2), 419-425 (2004). (Pubitemid 39187980)
43. Liu Z, Bhattacharyya S, Ning B et al. Plant-expressed recombinant mountain cedar allergen Jun a 1 is allergenic and has limited pectate lyase activity. Int. Arch. Allergy Immunol. 153(4), 347-358 (2010).
44. Esch RE. Grass pollen allergens. Clin. Allergy Immunol. 18, 185-205 (2004).
45. Weber RW. Patterns of pollen cross-allergenicity. J. Allergy Clin. Immunol. 112(2), 229-239; quiz 240 (2003). (Pubitemid 36981357)
46. Andersson K, Lidholm J. Characteristics and immunobiology of grass pollen allergens. Int. Arch. Allergy Immunol. 130(2), 87-107 (2003). (Pubitemid 36351233)
47. Sekerkova A, Polackova M, Striz I. Detection of Phl p 1, Phl p 5, Phl p 7 and Phl p 12 specific IgE antibodies in the sera of children and adult patients allergic to Phleum pollen. Allergol. Int. 61(2), 339-346 (2012).
48. Laffer S, Spitzauer S, Susani M et al. Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. J. Allergy Clin. Immunol. 98(3), 652-658 (1996). (Pubitemid 26377931)
49. Vrtala S, Sperr WR, Reimitzer I et al. cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen; characterization of the recombinant Phl pV allergen. J. Immunol. 151(9), 4773-4781 (1993). (Pubitemid 23318530)
50. Vrtala S, Susani M, Sperr WR et al. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). J. Allergy Clin. Immunol. 97(3), 781-787 (1996). (Pubitemid 26089252)
51. Suck R, Kamionka T, Schaffer B et al. Bacterially expressed and optimized recombinant Phl p 1 is immunobiochemically equivalent to natural Phl p 1. Biochim. Biophys. Acta 1764(11), 1701-1709 (2006). (Pubitemid 46053863)
52. Ball T, Fuchs T, Sperr WR et al. B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J. 13(11), 1277-1290 (1999). (Pubitemid 29382497)
53. Focke M, Mahler V, Ball T et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 15(11), 2042-2044 (2001).
54. Ball T, Linhart B, Sonneck K et al. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination. Allergy 64(4), 569-580 (2009).
55. Levin M, Rydnert F, Kallstrom E et al. Phl p 1-specific human monoclonal IgE and design of a hypoallergenic group 1 grass pollen allergen fragment. J. Immunol. 191(2), 551-560 (2013).
56. Schramm G, Kahlert H, Suck R et al. 'Allergen engineering': variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J. Immunol. 162(4), 2406-2414 (1999). (Pubitemid 29288869)
57. Wald M, Kahlert H, Reese G et al. Hypoallergenic mutants of the Timothy grass pollen allergen Phl p 5 generated by proline mutations. Int. Arch. Allergy Immunol. 159(2), 130-142 (2012).
58. Vrtala S, Focke M, Kopec J et al. Genetic engineering of the major timothy grass pollen allergen, Phl p 6, to reduce allergenic activity and preserve immunogenicity. J. Immunol. 179(3), 1730-1739 (2007).
59. Westritschnig K, Linhart B, Focke-Tejkl M et al. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin. J. Immunol. 179(11), 7624-7634 (2007).
60. Tripodi S, Frediani T, Lucarelli S et al. Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: implications for specific immunotherapy. J. Allergy Clin. Immunol. 129(3), 834-839.e838 (2012).
61. Linhart B, Jahn-Schmid B, Verdino P et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J. 16(10), 1301-1303 (2002).
62. Linhart B, Hartl A, Jahn-Schmid B et al. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J. Allergy Clin. Immunol. 115(5), 1010-1016 (2005). (Pubitemid 40616216)
63. Linhart B, Mothes-Luksch N, Vrtala S, Kneidinger M, Valent P, Valenta R. A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biol. Chem. 389(7), 925-933 (2008).
64. Hauser M, Ferreira F, Gadermaier G. Allergens of weed pollen: an overview on recombinant and natural molecules. Methods doi:10.1016/j.ymeth.2013.06.014 (2013) (Epub ahead of print).
65. Hauser M, Roulias A, Ferreira F, Egger M. Panallergens and their impact on the allergic patient. Allergy Asthma Clin. Immunol. 6(1), 1 (2010).
66. Siegert M, Pertl-Obermeyer H, Gadermaier G, Ferreira F, Obermeyer G. Expression of the major mugwort pollen allergen Art v 1 in tobacco plants and cell cultures: problems and perspectives for allergen production in plants. Plant Cell Rep. 31(3), 561-571 (2012).
67. Wopfner N, Jahn-Schmid B, Schmidt G et al. The alpha and beta subchain of Amb a 1, the major ragweed-pollen allergen show divergent reactivity at the IgE and T-cell level. Mol. Immunol. 46(10), 2090-2097 (2009).
68. Jahn-Schmid B, Wopfner N, Hubinger G et al. The T-cell response to Amb a 1 is characterized by 3 dominant epitopes and multiple MHC restriction elements. J. Allergy Clin. Immunol. 126(5), 1068-1071, 1071 e1061-1062 (2010).
69. Jahn-Schmid B, Hauser M, Wopfner N et al. Humoral and cellular cross-reactivity between Amb a 1, the major ragweed pollen allergen, and its mugwort homolog Art v 6. J. Immunol. 188(3), 1559-1567 (2012).
70. Czerwinski EW, Midoro-Horiuti T, White MA, Brooks EG, Goldblum RM. Crystal structure of Jun a 1, the major cedar pollen allergen from Juniperus ashei, reveals a parallel beta-helical core. J. Biol. Chem. 280(5), 3740-3746 (2005). (Pubitemid 40223842)
71. Gadermaier G, Wopfner N, Wallner M et al. Array-based profiling of ragweed and mugwort pollen allergens. Allergy 63(11), 1543-1549 (2008).
72. Himly M, Jahn-Schmid B, Dedic A et al. Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein with a defensin-like and a hydroxyproline-rich domain. FASEB J. 17(1), 106-108 (2003).
73. Razzera G, Gadermaier G, De Paula V et al. Mapping the interactions between a major pollen allergen and human IgE antibodies. Structure 18(8), 1011-1021 (2010).
74. Gadermaier G, Jahn-Schmid B, Vogel L et al. Targeting the cysteine-stabilized fold of Art v 1 for immunotherapy of Artemisia pollen allergy. Mol. Immunol. 47(6), 1292-1298 (2010).
75. Gadermaier G, Dedic A, Obermeyer G, Frank S, Himly M, Ferreira F. Biology of weed pollen allergens. Curr. Allergy Asthma Rep. 4(5), 391-400 (2004). (Pubitemid 39232735)
76. Duro G, Colombo P, Costa MA et al. cDNA cloning, sequence analysis and allergological characterization of Par j 2.0101, a new major allergen of the Parietaria judaica pollen. FEBS Lett. 399(3), 295-298 (1996). (Pubitemid 26426868)
77. Tordesillas L, Sirvent S, Diaz-Perales A et al. Plant lipid transfer protein allergens: no cross-reactivity between those from foods and olive and Parietaria pollen. Int. Arch. Allergy Immunol. 156(3), 291-296 (2011).
78. Bonura A, Amoroso S, Locorotondo G et al. Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the non-specific lipid transfer protein plant family. Int. Arch. Allergy Immunol. 126(1), 32-40 (2001). (Pubitemid 32973970)
79. Orlandi A, Grasso F, Corinti S et al. The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization. Clin. Exp. Allergy 34(3), 470-477 (2004). (Pubitemid 38373012)
80. Costa MA, Duro G, Izzo V et al. The IgE-binding epitopes of rPar j 2, a major allergen of Parietaria judaica pollen, are heterogeneously recognized among allergic subjects. Allergy 55(3), 246-250 (2000). (Pubitemid 30146120)
81. Pace E, Duro G, La Grutta S et al. Hypoallergenic fragment of Par j 2 increases functional expression of Toll-like receptors in atopic children. Allergy 61(12), 1459-1466 (2006). (Pubitemid 44665312)
82. Bonura A, Corinti S, Artale A et al. A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. Int. Arch. Allergy Immunol. 142(4), 274-284 (2007). (Pubitemid 46425807)
83. Bonura A, Passantino R, Costa MA et al. Characterization of a Par j 1/Par j 2 mutant hybrid with reduced allergenicity for immunotherapy of Parietaria allergy. Clin. Exp. Allergy 42(3), 471-480 (2012).
84. Gonzalez-Rioja R, Ibarrola I, Arilla MC et al. Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy. J. Allergy Clin. Immunol. 120(3), 602-609 (2007). (Pubitemid 47320743)
85. Nouri HR, Varasteh A, Vahedi F, Chamani J, Afsharzadeh D, Sankian M. Constructing a hybrid molecule with low capacity of IgE binding from Chenopodium album pollen allergens. Immunol. Lett. 144(1-2), 67-77 (2012).
86. Nouri HR, Sankian M, Afsharzadeh D, Varasteh A. Immunotherapy with a recombinant hybrid molecule alleviates allergic responses more efficiently than an allergenic cocktail or pollen extract in a model of Chenopodium album allergy. Int. Arch. Allergy Immunol. 161(4), 325-332 (2013).
87. Assarehzadegan MA, Sankian M, Jabbari F, Tehrani M, Varasteh A. Expression of the recombinant major allergen of Salsola kali pollen (Sal k 1) and comparison with its low-immunoglobulin E-binding mutant. Allergol. Int. 59(2), 213-222 (2010).
88. Klimek L, Schendzielorz P, Pinol R, Pfaar O. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study. Clin. Exp. Allergy 42(6), 936-945 (2012).
89. Larenas-Linnemann D. Oralair birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Curr. Opin. Investig. Drugs 11(5), 586-596 (2010).
90. Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl Acad. Sci. USA 101 (Suppl. 2), 14677-14682 (2004). (Pubitemid 39346742)
91. Purohit A, Niederberger V, Kronqvist M et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin. Exp. Allergy 38(9), 1514-1525 (2008).
92. Pellaton C, Perrin Y, Boudousquie C et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin. Transl. Allergy 3(1), 17 (2013).
93. Fellrath JM, Kettner A, Dufour N et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a Phase I trial. J. Allergy Clin. Immunol. 111(4), 854-861 (2003). (Pubitemid 36470260)
94. Etto T, de Boer C, Prickett S et al. Unique and cross-reactive T cell epitope peptides of the major Bahia grass pollen allergen, Pas n 1. Int. Arch. Allergy Immunol. 159(4), 355-366 (2012).
95. Hafner RP, Salapatek A, Patel D, Larché M, Laidler P. Validation of peptide immunotherapy as a new approach in the treatment of allergic rhinoconjunctivitis: the clinical benefits of treatment with Amb a 1 derived T cell epitopes. J. Allergy Clin. Immunol. 129(Suppl. 2), AB368 (2012).
96. Midoro-Horiuti T, Goldblum RM, Kurosky A, Goetz DW, Brooks EG. Isolation and characterization of the mountain cedar (Juniperus ashei) pollen major allergen, Jun a 1. J. Allergy Clin. Immunol. 104(3 Pt 1), 608-612 (1999). (Pubitemid 29451651)
97. Gadermaier G, Hauser M, Ferreira F. Allergens of weed pollen: an overview on recombinant and natural molecules. Methods doi: 10.1016/j.ymeth.2013.06.014 (2013) (Epub ahead of print).
98. Winther L, Poulsen LK, Robin B, Melac M, Malling HJ. Safety and tolerability of recombinant Bet v 1 (rBet v 1) tablets in sublingual immunotherapy (SLIT). J. Allergy Clin. Immunol. 123(Suppl.), S215 (2009).